Physician profile
Heidi E Ogden
NPI 1952334765
$55,474.36
in general payments reported to CMS, 2019-2025
20 companies · $33K in 2025
The $33K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.73 · 2020: $67.69 · 2021: $90.34 · 2022: $125 · 2023: $10K · 2024: $12K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $2,555 · Travel and Lodging: $1,721 · Consulting Fee: $460 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,191.00 |
| Food and Beverage | $2,554.88 |
| Travel and Lodging | $1,721.49 |
| Consulting Fee | $460.00 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $53,351.29 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $453.25 | 2019-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $264.54 | 2024-2025 | Auvelity |
| Abbvie INC. | $170.65 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $153.32 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $145.57 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $127.10 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.63 | 2023-2025 | Caplyta |
| Alkermes, INC. | $113.12 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $85.67 | 2024-2025 | Ingrezza |
| Almatica Pharma LLC | $73.30 | 2023-2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $65.27 | 2021-2024 | Qelbree, Qelbree |
| Indivior INC. | $60.43 | 2023-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $59.23 | 2024 | |
| Jazz Pharmaceuticals INC. | $53.62 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.66 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $45.56 | 2024-2025 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $41.87 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $30.44 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $15.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.